Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

iOWH 032

Next Previous
X
Search
Drug Profile

iOWH 032

Alternative Names: iOWH032

Latest Information Update: 14 Nov 2019

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute for OneWorld Health
  • Developer Institute for OneWorld Health; PATH
  • Class Amides; Antidiarrhoeals; Bromobenzenes; Heterocyclic compounds; Oxadiazoles; Phenyl ethers; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diarrhoea

Most Recent Events

  • 04 Nov 2019 Path plans a phase I trial for Diarrhoea in November 2019 (PO)(NCT04150250)
  • 04 Apr 2014 PATH & the Bill and Melinda Gates Foundation plan a phase II trial for Diarrhoea (due to cholera) in Bangladesh (NCT02111304)
  • 26 Nov 2013 The Institute for OneWorld Health & the Program for Appropriate Technology in Health complete a phase I/II trial in Diarrhoea (due to cholera) in Bangladesh (NCT01823939)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top